Trial Profile

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Chinese Patients With Advanced or Metastatic HR+/HER2- Breast Cancer and Other Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BGB-43395 (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors BeOne Medicines

27 May 2025 According to BeOne Medicines media release, BeiGene is now called BeOne Medicines
20 May 2025 Status changed from recruiting to active, no longer recruiting.
27 Feb 2025 According to a BeiGene media release, proof-of-concept data expected in the first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com